Feasibility of 4 cycles of docetaxel and cyclophosphamide every 14 days as an adjuvant regimen for breast cancer: a Wisconsin Oncology Network study. - Wikidata - wikimedia - TriplyDB

Feasibility of 4 cycles of docetaxel and cyclophosphamide every 14 days as an adjuvant regimen for breast cancer: a Wisconsin Oncology Network study.

Feasibility of 4 cycles of docetaxel and cyclophosphamide every 14 days as an adjuvant regimen for breast cancer: a Wisconsin Oncology Network study.

http://www.wikidata.org/entity/Q37724850

about

Pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors.Cyclophosphamide administration routine in autoimmune rheumatic diseases: a review.Update on adjuvant chemotherapy for early breast cancer

P2860

Q38613025-B14679C8-13F3-4759-9A27-08910DC8EC32 Q38969688-811DF83C-13DC-49A5-83AE-4904B49A00FD Q57126532-6E89B2F1-A137-4EC9-9E67-06F5DD464E70

P2860

Feasibility of 4 cycles of docetaxel and cyclophosphamide every 14 days as an adjuvant regimen for breast cancer: a Wisconsin Oncology Network study.

http://www.wikidata.org/entity/Q37724850

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 26 October 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Feasibility of 4 cycles of doc ...... consin Oncology Network study.

@en

Feasibility of 4 cycles of doc ...... consin Oncology Network study.

@nl

type

label

Feasibility of 4 cycles of doc ...... consin Oncology Network study.

@en

Feasibility of 4 cycles of doc ...... consin Oncology Network study.

@nl

prefLabel

Feasibility of 4 cycles of doc ...... consin Oncology Network study.

@en

Feasibility of 4 cycles of doc ...... consin Oncology Network study.

@nl

P1433

Q37724850-DE7A2D4D-4E7C-49DE-BDC2-FD6DE6F0C948

P1476

Q37724850-ED0978B9-8BC9-4B52-B93F-29BBA579F2B3

P2093

Q37724850-029F0DDA-FD63-4236-9998-0FB71FD27DAF

Q37724850-0328181B-A0AF-4870-B9B0-38182557A0D3

Q37724850-07676C7D-83F0-4177-8180-18E2B8DF4EDF

Q37724850-278E5B93-1E77-44E8-B4D0-C2ECA39A6039

Q37724850-3B7C0FCF-4180-48D7-AFC7-3F127CF54AB5

Q37724850-4545BE9B-CA4D-4725-B9E1-3FCD66FADC9D

Q37724850-48B8DA61-4506-41A0-AF6C-E6894C44B1F1

Q37724850-7C694B06-8E85-4AAC-9416-0CEF256751AB

Q37724850-82E8684C-6F27-46AD-ABE5-0695297F3738

Q37724850-882194F9-19B5-4270-A3C3-93CB45EB1564

P2860

Q37724850-02CCDC84-68D8-48B5-9A84-C9BC1B40D2ED

Q37724850-0560A845-4513-44C3-ADDD-2721CDB3B519

Q37724850-1057BF91-1D6D-479D-A705-6E35C6C294B5

Q37724850-30CAED57-5EF2-4388-8897-1E77A622C20B

Q37724850-3A573E23-4282-427E-A778-3689FACC1626

Q37724850-4689B472-F737-4727-8C0A-B3758E6F6294

Q37724850-5698F334-969C-469F-B2FE-2259EAC8CF10

Q37724850-637348C5-8A4C-4B71-8D9F-B7902BDEBD13

Q37724850-67E0848B-BAAF-420F-9409-931232932188

Q37724850-696B66F2-739B-4BC1-87C2-A56D3778A695

P304

Q37724850-47432C15-B6C2-40AE-8583-D5B73A5D2EC5

P31

Q37724850-A4CF26C0-A585-4065-9AB4-29DF6C96F18D

P356

Q37724850-0BAF3992-5FC0-47EE-86EA-633485133E23

P407

Q37724850-7FA056A1-3DB1-4C4E-95AB-0FAF3EBF2937

P433

Q37724850-D1693EA8-B46B-41B2-B3D6-A7EE05D0D2CC

P478

Q37724850-277562C7-D664-4DE5-972C-A6116C4CA3DD

P50

Q37724850-E9E670AC-9E0E-4297-8787-948B1F534CE0

P577

Q37724850-45E39DB6-496B-4BEA-B25D-0EF9E5031226

P5875

Q37724850-3775EFDB-A941-4331-B973-AF041B171B5A

P698

Q37724850-A6A1C613-55C6-4DE3-AC5A-F12E11BB0768

P932

Q37724850-D3020442-4466-4E6A-8804-173294431E1D

P356

J.CLBC.2013.10.018

P1433

Clinical Breast Cancer

P1476

Feasibility of 4 cycles of doc ...... consin Oncology Network study.

@en

P2093

Amy Stella

http://www.w3.org/2001/XMLSchema#string

Amye J Tevaarwerk

http://www.w3.org/2001/XMLSchema#string

Anne M Traynor

http://www.w3.org/2001/XMLSchema#string

Kari B Wisinski

http://www.w3.org/2001/XMLSchema#string

Kyungmann Kim

http://www.w3.org/2001/XMLSchema#string

Leah Dietrich

http://www.w3.org/2001/XMLSchema#string

Patrick Mansky

http://www.w3.org/2001/XMLSchema#string

Robert Hegeman

http://www.w3.org/2001/XMLSchema#string

Rubina Qamar

http://www.w3.org/2001/XMLSchema#string

Sarahmaria Donohue

http://www.w3.org/2001/XMLSchema#string

P2860

Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial.

Adjuvant breast cancer therapy: current status and future strategies--growth kinetics and the improved drug therapy of breast cancer.

Molecular cloning and expression of cDNA for human granulocyte colony-stimulating factor.

Purification and biochemical characterization of human pluripotent hematopoietic colony-stimulating factor.

High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials.

The cost-utility of adjuvant chemotherapy using docetaxel and cyclophosphamide compared with doxorubicin and cyclophosphamide in breast cancer.

Impact of colony-stimulating factors to reduce febrile neutropenic events in breast cancer patients receiving docetaxel plus cyclophosphamide chemotherapy.

Evolving concepts in the systemic drug therapy of breast cancer.

Cost-effectiveness analysis of adjuvant therapy for operable breast cancer from a Chinese perspective: doxorubicin plus cyclophosphamide versus docetaxel plus cyclophosphamide.

High rate of febrile neutropenia in patients with operable breast cancer receiving docetaxel and cyclophosphamide.

P304

205-211

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CLBC.2013.10.018

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-10-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259161511

http://www.w3.org/2001/XMLSchema#string

P698

24342730

http://www.w3.org/2001/XMLSchema#string

P932

4000576

http://www.w3.org/2001/XMLSchema#string